Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: Antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients

European Neuropsychopharmacology

Volumn 20, Issue 10, 2010, Pages 721-730

  García Sevilla, Jesús A ^a,b   Álvaro Bartolomé, María ^a,b   Díez Alarcia, Rebeca ^c,d   Ramos Miguel, Alfredo ^a,b   Puigdemont, Dolors ^d,e   Pérez, Víctor ^d,e   Alvarez, Enric ^d,e   Meana, J Javier ^c,d  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b Red Temática de Investigación Cooperativa en Salud RETICS Trastornos Adictivos   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Lymphocyte GRK2 5 mRNAs; Major depressive disorder; Platelet GRK2 3 5 proteins; SNRIs; SSRIs

Indexed keywords

DULOXETINE; ESCITALOPRAM; FLUOXETINE; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 5; MESSENGER RNA; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; LYMPHOCYTE; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; ANTIDEPRESSIVE AGENTS; BLOOD PLATELETS; DEPRESSIVE DISORDER, MAJOR; DOWN-REGULATION; DRUG RESISTANCE; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; G-PROTEIN-COUPLED RECEPTOR KINASE 3; G-PROTEIN-COUPLED RECEPTOR KINASE 5; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; RECEPTORS, ADRENERGIC; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS; UP-REGULATION;

EID: 77956177387     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.04.008     Document Type: Article

References (55)

1. Álvarez E., Pérez-Solá V., Pérez-Blanco J., Queraltó J.M., Torrubia R., Noguera R. Predicting outcome of lithium added to antidepressants in resistant depression. J. Affect. Disord. 1997, 42:179-186.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, APA, APA, Washington, DC. 4th ed.
3. Belmaker R.H., Agam G. Major depressive disorder. N. Engl. J. Med. 2008, 358:55-68.
4. 2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J. Neurochem. 1998, 70:1114-1123.
5. Charney D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J. Clin. Psychiatry 1998, 59:11-14.
6. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctôt K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2009, 67:446-457.
7. Dromey J.R., Pfleger K.D.G. G protein coupled receptors as drug targets: the role of β-arrestins. Endocr. Metab. Immune Disord. Drug Targets 2008, 8:51-61.
8. Dwivedi Y., Rizavi H.S., Roberts R.C., Conley R.C., Tamminga C.A., Pandey G.N. Reduced activation and expression of ERK1/2 MAP kinase in post-mortem brain of depressed suicide subjects. J. Neurochem. 2001, 77:916-928.
9. Dwivedi Y., Rizavi H.S., Zhang H., Roberts R.C., Conley R.R., Pandey G.N. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). Int. J. Neuropsychopharmacol. 2009, 12:1337-1354.
10. Elorza A., Sarnago S., Mayor F. Agonist-dependent modulation of G protein-coupled receptor kinase 2 by mitogen-activated protein kinases. Mol. Pharmacol. 2000, 57:778-783.
11. Elorza A., Penela P., Sarnago S., Mayor F. MAPK-dependent degradation of G protein-coupled receptor kinase 2. J. Biol. Chem. 2003, 278:29164-29173.
12. Ertley R.N., Bazinet R.P., Lee H.-J., Rapoport S.I., Rao J.S. Chronic treatment with mood stabilizers increases membrane GRK3 in rat frontal cortex. Biol. Psychiatry 2007, 61:246-249.
13. 1A-autoreceptors regulating monoamine synthesis in rat brain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 1999, 360:135-143.
14. 2O PET study of the neuromodulatory effects of clonidine. Biol. Psychiatry 2001, 49:317-325.
15. García-Fuster M.J., Miralles A., García-Sevilla J.A. Effects of opiate drugs on Fas-associated protein with death domain (FADD) and effector caspases in the rat brain: regulation by the ERK1/2 MAP kinase pathway. Neuropsychopharmacology 2007, 32:399-411.
16. 2-adrenergic receptors in major depressive disorder: binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. Arch. Gen. Psychiatry 1981, 38:1327-1333.
17. 2-adrenoceptors in major affective disorder. Arch. Gen. Psychiatry 1986, 43:51-57.
18. 2-Adrenoceptor-mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression. Arch. Gen. Psychiatry 1990, 47:125-132.
19. 2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J. Neurochem. 1999, 72:282-291.
20. 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology 2004, 29:580-588.
21. 2A-adrenoceptors. Mol. Psychiatry 2002, 7:755-767.
22. Grange-Midroit M., García-Sevilla J.A., Ferrer-Alcón M., La Harpe R., Walzer C., Guimón J. G protein-coupled receptor kinases, β-arrestin-2 and associated regulatory proteins in the human brain: postmortem changes, effect of age and subcellular distribution. Mol. Brain Res. 2002, 101:39-51.
23. Grange-Midroit M., García-Sevilla J.A., Ferrer-Alcón M., La Harpe R., Huguelet P., Guimón J. Regulation of GRK 2 and 6, β-arrestin-2 and associated proteins in the prefrontal cortex of drug-free and antidepressant drug-treated subjects with major depression. Mol. Brain Res. 2003, 111:31-41.
24. 2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. Psychiatry Res. 1999, 89:73-95.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1967, 6:278-296.
26. Heninger G.R., Delgado P.L., Charney D.S. The revised monoamine theory of depression: a modulatory role of monoamines, based on new findings from depletion experiments in humans. Pharmacopsychiatry 1996, 29:2-11.
27. Johnson L.R., Scott M.G.H., Pitcher J.A. G protein-coupled receptor kinase 5 contains a DNA-binding nuclear localization sequence. Mol. Cell. Biol. 2004, 24:10169-10179.
28. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
29. Lefkowitz R.J. G protein-coupled receptors. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J. Biol. Chem. 1998, 273:18677-18680.
30. Lindemann S., Tolley N.D., Dixon D.A., McIntyre T.M., Prescott S.M., Zimmerman G.A., Weyrich A.S. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J. Cell. Biol. 2001, 154:485-490.
31. Lombardi M.S., Kavelaars A., Schedlowski M., Bijlsma J.W.J., Okihara K.L., Van de Pol M., Ochsmann S., Pawlak C., Schmidt R.E., Heijnen C.J. Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cell of pateints with rheumatoid arthritis. FASEB J. 1999, 13:715-725.
32. Lucassen P.J., Meerlo P., Naylor A.S., van Dam A.M., Dayer A.G., Fuchs E., Oomen C.A., Czéh B. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: implications for depression and antidepressant action. Eur. Neuropsychopharmacol. 2010, 20:1-17.
33. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoollaeghe E., Ranjan R., Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 1995, 34:301-309.
34. Martini J.S., Raake P., Vinge L.E., DeGeorge B.R., Chuprun J.K., Harris D.M., Gao E., Eckhart A.D., Pitcher J.A., Koch W.J. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12457-12462.
35. Mason K.D., Carpinelli M.R., Fletcher J.I., Collinge J.E., Hilton A.A., Ellis S., Kelly P.N., Ekert P.G., Metcalf D., Roberts A.W., Huang D.C.S., Kile B.T. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
36. Matuzany-Ruban A., Golan M., Miroshnik N., Schreiber G., Avissar S. Normalization of GRK2 protein and mRNA measures in patients with depression predict response to antidepressants. Int. J. Neuropsychopharmacol. 2010, 13:83-91.
37. Mazharian A., Watson S.P., Séverin S. Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation. Exp. Hematol. 2009, 37:1238-1249.
38. Miralles A., Asensio V.J., García-Sevilla J.A. Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein-coupled receptor kinases 2/3 in rat brain. Neuropharmacology 2002, 43:1249-1257.
39. Niculescu A.B., Segal D.S., Kuczenski R., Barrett T., Hauger R.L., Kelsoe J.R. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol. Genomics 2000, 4:83-91.
40. Nutt D.J. The neuropharmacology of serotonin and noradrenaline in depression. Int. Clin. Psycopharmacol. 2002, 17(Suppl. 1):S1-S12.
41. 2-adrenoceptors in the locus coeruleus in major depression. Biol. Psychiatry 2003, 53:315-323.
42. Ozaita A., Escribá P.V., Ventayol P., Murga C., Mayor F., García-Sevilla J.A. Regulation of G protein-coupled receptor kinase 2 in brains of opiate-treated rats and human opiate addicts. J. Neurochem. 1998, 70:1249-1257.
43. Pålhagen, S., Qi, H., Mårtensson, B., Wålinder, J., Granérus, A.K., Svenningsson, P., 2010. Momoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J. Neurol. 257, 524-532.
44. Penela P., Ruiz-Gómez A., Castaño J.G., Mayor F. Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J. Biol. Chem. 1998, 273:35238-35244.
45. Pierce K.L., Luttrell L.M., Lefkowitz R.J. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001, 20:1532-1539.
46. Piletz J.E., Halaris A., Saran A., Marler M. Desipramine lowers tritiated paraaminoclonidine binding in platelets of depressed patients. Arch. Gen. Psychiatry 1991, 48:813-820.
47. Pitcher J.A., Tesmer J.J.G., Freeman J.L.R., Capel W.D., Stone W.C., Lefkowitz R.J. Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J. Biol. Chem. 1999, 274:34531-34534.
48. Premont R.T., Gainetdinov R.R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 2007, 69:511-534.
49. Rao J.S., Rapoport S.I., Kim H.-W. Decreased GRK3 but not GRK2 expression in frontal cortex from bipolar disorder patients. Int. J. Psychopharmacol. 2009, 12:851-860.
50. Ressler K.J., Nemeroff C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 1999, 46:1219-1233.
51. Shaltiel G., Shamir A., Levi I., Bersudsky Y., Agam G. Lymphocyte G-protein receptor kinase (GRK)3 mRNA levels in bipolar disorder. Int. J. Neuropsychopharmacol. 2006, 9:761-766.
52. Suo Z., Wu M., Citron B.A., Wong G.T., Festoff B.W. Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early β-amyloid accumulation. J. Neurosci. 2004, 24:3444-3452.
53. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Amended by the 59th WMA General Assembly, Seoul, October 2008 2008, World Medical Association.
54. 2-Adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J. Neurosci. 2010, 30:1096-1109.
55. Ziegelstein R.C., Parakh K., Sakhuja A., Bhat U. Platelet function in patients with major depression. Inter. Med. J. 2009, 39:38-43.